Seneca Therapeutics, Inc. Appoints Cuong Do to its Board of Directors
Seneca Therapeutics, Inc. (STI), a biotech company focusing on neuroendocrine neoplasm (NEN) cancer programs, has announced the appointment of Cuong Do, MBA to its Board of Directors. Mr. Do is currently the President and Chief Executive Officer of BioVie Inc. He has served for more than two decades as a senior strategy officer in the biotech and pharmaceutical industries.
Excitement Over Do’s Appointment
James Hussey, the Chief Executive Officer of Seneca Therapeutics welcomed that Do has successfully financed and led several life science biotech companies across a range of therapeutic areas, he also pointed out that Do’s experience in the pharmaceutical and biotechnology industries aligns strategically with the long-term Research & Development goals of the company. Mr. Hussey is excited about deepening the relationship between Seneca Therapeutics and other leading biopharmaceutical companies. In addition, Do’s extensive executive leadership experience and strategic expertise can help Seneca Therapeutics advance its NEN cancer programs towards late-stage trials.
Do’s Perspective and Contribution to the Company’s Evolution
Mr. Do expressed excitement to join Seneca Therapeutics at this crucial stage in the company’s evolution. He cited that clinical data of SVV-001 has already demonstrated significant patient benefit in many cancer indications, particularly in NEN cancer. He further explained that SVV-001’s potential to work with checkpoint inhibition and drive objective responses in NEN is very promising. In addition, SVV-001’s upcoming clinical trial in patients with NEN cancer will provide valuable opportunities to accelerate its path towards registration in these indications. Do looks forward to contributing his insights into the company management and the board as they prepare for anticipated growth.
Do’s Professional Background
Mr. Do comes to the board of STI with a wealth of experience spanning over two decades as a former senior partner at McKinsey & Company, where he helped build the health care, high tech, and corporate finance practices. Before his appointment with BioVie, Do was President of Samsung Electronics Co., Ltd. Global Strategy Group and Chief Strategy Officer for Merck and Company, a leading US pharmaceuticals company. He holds a BA from Dartmouth College and an MBA from the Tuck School of Business at Dartmouth College.
About Seneca Therapeutics
Seneca Therapeutics was established to take advantage of the huge tumor specificity of SVV-001 and further develop it in multiple clinical trials. STI aims to create and test armed derivatives expressing gene product(s) selectively inserted into the genome of SVV-001 that can offer additional anti-tumor impact.
Final Thoughts and Recommendations
The appointment of Cuong Do, MBA, to the Board of Directors of Seneca Therapeutics, is one that the company views as critical. Do’s background in the pharmaceutical and biotechnology industries and his extensive executive leadership experience and strategic expertise will be of enormous value as Seneca Therapeutics advances its NEN cancer programs. The upcoming clinical trial of SVV-001 in NEN cancer patients will provide an excellent opportunity for the company to accelerate its path to registration in these indications. Seneca Therapeutics has a bright future with the potential for significant patient benefit, something that all stakeholders should applaud.
<< photo by Tirachard Kumtanom >>
